Nephropathy in patients with type 2 diabetes mellitus

New England Journal of Medicine

Volumn 341, Issue 15, 1999, Pages 1127-1133

  Ritz, Eberhard ^a   Orth, Stephan Reinhold ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETIC NEPHROPATHY; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE; KIDNEY FAILURE, CHRONIC; RISK FACTORS;

EID: 0033533807     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199910073411506     Document Type: Review

References (65)

1. Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT. The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients. Kidney Int 1982;21:730-8.
2. Ritz E, Stefanski A. Diabetic ncphropathy in type II diabetes. Am J Kidney Dis 1996;27:167-94.
3. Renal Data System. USRDS 1998 annual data report. Bethesda, Md.: National Institute of Diabetes and Digestive and Kidney Diseases, April 1998. (NIH publication no. 98-3176.)
4. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes - a medical catastrophe of worldwide dimensions. Am J Kidney Dis (in press).
5. Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 1989;4:859-63.
6. Chantrel F, Enache I, Bouiller M, et al. Abysmal prognosis of patients with type 2 diabetes entering dialysis. Nephrol Dial Transplant 1999;14: 129-36.
7. Fioretto P, Maurer M, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996;39:1569-76.
8. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990;33: 438-43.
9. Keller CK, Bergis KH, Fliser D, Ritz E. Renal findings in patients with short-term type 2 diabetes. J Am Soc Nephrol 1996;7:2627-35.
10. Strojek K, Grzeszczak W, Morawin E, et al. Nephropathy of type II diabetes: evidence for hereditary factors? Kidney Int 1997;51:1602-7.
11. Bowden DW, Sale M, Howard TD, et al. Linkage of genetic markers on human chromosomes 20 and 12 to NIDDM in Caucasian sib pairs with a history of diabetic nephropathy. Diabetes 1997;46:882-6.
12. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Diabetes 1998; 47:821-30.
13. Tarnow L, Gluud C, Parving H-H. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 1998;13:1125-30.
14. Jeffers BW, Estacio RO, Raynolds MV, Schrier RW. Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy. Kidney Int 1997; 52:473-7.
15. + exchange in erythrocytes of patients with NIDDM: a prospective study. Diabetologia 1997;40:302-6.
16. Krolewski AS. Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int 1999;55:1582-96.
17. Blüthner M, Schmidt S, Siffert W, Knigge H, Nawroth P, Ritz E. Increased frequency of G-protein β3-subunit 825 T allele in dialyzed patients with type 2 diabetes. Kidney Int 1999;55:1247-50.
18. Gall M-A, Rossing P, Skøtt P, et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991;34:655-61.
19. Olivarius N de F, Andreasen AH, Keiding N, Mogensen CE. Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients: cross-sectional data from the population-based study "Diabetes Care in General Practice," Denmark. Diabetologia 1993;36: 1007-16.
20. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998;11: 998-1004.
21. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989;321:1074-9.
22. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med 1993;329:977-86.
23. Kawazu S, Tomono S, Shimizu M, et al. The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus: the effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study. J Diabetes Complications 1994;8:13-7.
24. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
25. Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999;55:1-28.
26. Orth SR, Ritz E, Schrier RW. The renal risks of smoking. Kidney Int 1997;51:1669-77.
27. Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 1994;9:1097-102.
28. Sawicki PT, Didjurgeit U, Mühlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994;17:126-31.
29. Toeller M, Buyken A, Heitkamp G, et al. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia 1997;40:1219-26.
30. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991;324:78-84.
31. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Jarvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. Hypertension 1997;30:1144-9.
32. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995;346: 1080-4.
33. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-9.
34. Nakano S, Fukuda M, Hotta F, et al. Reversed circadian blood pressure rhythm is associated with occurrences of both fetal and nonfatal vascular events in NIDDM subjects. Diabetes 1998;47:1501-6.
35. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 1999;42:263-85.
36. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997;46:1182-8.
37. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62.
38. Jacobson HR, Striker GE. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. Am J Kidney Dis 1995;25:103-6.
39. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-56.
40. Yokoyama H, Tomonaga O, Hirayama M, et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 1997;40: 405-11.
41. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13. [Erratum, BMJ 1999;318:29.]
42. Mogensen CE. Combined high blood pressure and glucose in type 2 diabetes: double jeopardy: British trial shows dear effects of treatment, especially blood pressure reduction. BMJ 1998;317:693-4.
43. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
44. Ruilope LM, Garcia-Robles R. How far should blood pressure be reduced in diabetic hypertensive patients? J Hypertens Suppl 1997;15:S63-S65.
45. Christensen PK, Hansen HP, Parving HH. Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney Int 1997;52:1369-74.
46. Weidmann P, Boehlen LM, de Courten M. Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 1993;8:582-4.
47. Lewis EJ, Hunsicker LG, Bain RP, Ronde RD. The effect of angiotensin-converting-enzymc inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62. [Erratum, N Engl J Med 1993;330:152.]
48. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.
49. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63.
50. Fisher NDL, Price DA, Litchfield WR, Williams GH, Hollenberg NK. Renal response to captopril reflects state of local renin system in healthy humans. Kidney Int 1999;56:635-41.
51. Wagner J, Gehlen F, Ciechanowicz A, Ritz E. Angiotensin II receptor type I gene expression in human glomerulonephritis and diabetes mellitus. J Am Soc Nephrol 1999;10:545-51.
52. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-81.
53. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92.
54. Gansevoort RT, de Zceuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:861-7.
55. Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int 1998;53:1559-73.
56. Guasch A, Parham M, Zayas CF, Campbell O, Nzerue C, Macon E. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. J Am Soc Nephrol 1997;8:793-8.
57. Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996;45:216-22.
58. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-50.
59. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
60. Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340:677-84.
61. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283-9.
62. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 1998; 98:2513-9.
63. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331;1416-20.
64. Erley CM. Does hydration prevent radiocontrast-induced acute renal failure? Nephrol Dial Transplant 1999;14:1064-6.
65. Hirschl MM. The patients with type II diabetes and uraemia - to transplant or not to transplant. Nephrol Dial Transplant 1995;10:1515-6.